How much did Gamida Cell achieve in EBIT for the current year?
In the current year, Gamida Cell has achieved an EBIT of -72.3 M USD.
Gamida Cell EBIT 2024
Gamida Cell EBIT
-72.3 M USD
Ticker
GMDAQ
ISIN
IL0011552663
WKN
A2N7XM
In 2024, Gamida Cell's EBIT was -72.3 M USD, a -0.47% increase from the -72.64 M USD EBIT recorded in the previous year.
The Gamida Cell EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2025e | 36.08 |
| 2024e | -72.3 |
| 2023 | -72.64 |
| 2022 | -74.99 |
| 2021 | -87.17 |
Gamida Cell Revenue, EBIT, Net Income IL0011552663 · A2N7XM
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Gamida Cell, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Gamida Cell from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Gamida Cell’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Gamida Cell. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Gamida Cell’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Gamida Cell’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Gamida Cell’s growth potential.
Gamida Cell Revenue, EBIT and net profit per share
| Date | Gamida Cell Revenue | Gamida Cell EBIT | Gamida Cell Net Income |
|---|---|---|---|
| 2025e | 190.63 M undefined | 36.08 M undefined | 26.97 M undefined |
| 2024e | 16.15 M undefined | -72.3 M undefined | -90.92 M undefined |
| 2023 | 1.78 M undefined | -72.64 M undefined | -63 M undefined |
| 2022 | 0 undefined | -74.99 M undefined | -79.38 M undefined |
| 2021 | 0 undefined | -87.17 M undefined | -89.79 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2021 | 0 USD | -87.17 M USD | -89.79 M USD |
| 2022 | 0 USD | -74.99 M USD | -79.38 M USD |
| 2023 | 1.78 M USD | -72.64 M USD | -63 M USD |
| 2024e | 16.15 M USD | -72.3 M USD | -90.92 M USD |
| 2025e | 190.63 M USD | 36.08 M USD | 26.97 M USD |
Gamida Cell stock margins IL0011552663 · A2N7XM
The Gamida Cell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Gamida Cell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Gamida Cell.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Gamida Cell's sales revenue. A higher gross margin percentage indicates that the Gamida Cell retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Gamida Cell's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Gamida Cell's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Gamida Cell's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Gamida Cell. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Gamida Cell's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Gamida Cell Margin History
| Gamida Cell Gross margin | Gamida Cell Profit margin | Gamida Cell EBIT margin | Gamida Cell Profit margin |
|---|---|---|---|
| 2025e | 18.5 % | 18.93 % | 14.15 % |
| 2024e | 18.5 % | -447.66 % | -562.93 % |
| 2023 | 18.5 % | -4,071.92 % | -3,531.17 % |
| 2022 | 18.5 % | 0 % | 0 % |
| 2021 | 18.5 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2021 | 18.5 % | 0 % | 0 % |
| 2022 | 18.5 % | 0 % | 0 % |
| 2023 | 18.5 % | -4,071.92 % | -3,531.17 % |
| 2024e | 18.5 % | -447.66 % | -562.93 % |
| 2025e | 18.5 % | 18.93 % | 14.15 % |
Gamida Cell Aktienanalyse
What does Gamida Cell do?
The company Gamida Cell Ltd was founded in 1998 in Jerusalem, Israel and is involved in the development and manufacture of cell therapy products for various diseases. The company has had an exciting history since its inception, including a number of successes and milestones. Gamida Cell's business model is based on the production of cell therapy products for patients suffering from severe diseases. These include blood diseases such as leukemia, lymphoma, or sickle cell anemia. The company uses a unique technology platform called "NiCord," which allows for the extraction and expansion of cells from umbilical cord blood to provide a larger number of cells for transplantation. This platform offers a way to overcome some of the limitations and challenges associated with the use of bone marrow or stem cell donors. Gamida Cell has made significant progress in the development of cell therapy products in recent years. The company is currently working on the development of therapies for various indications such as blood diseases, solid tumors, and autoimmune diseases. Another goal of Gamida Cell is to use its technology platform for the development of drugs for other indications. The company has various divisions in which it operates. The primary division is research and development of cell therapies. However, the company also has a manufacturing facility for the production of its products and a clinical studies department responsible for conducting studies and tests of therapeutics. Gamida Cell collaborates closely with research institutions and other companies in the biotechnology industry to further develop its technology platform and advance the progress of cell therapies overall. Gamida Cell currently offers a range of products, starting with its flagship product "NiCord." NiCord is a cell therapy made from umbilical cord blood cells and can be used for transplantation in patients with blood diseases such as leukemia or lymphoma. The company is also working on the development of additional products, including a cell therapy for solid tumors and a treatment for autoimmune diseases. In recent years, Gamida Cell has received several awards and recognitions. The company has attracted several leading scientists and researchers who collaborate closely with Gamida Cell to further develop the company's technology platform and create new therapies. At the same time, Gamida Cell has also carried out several capital increases to advance research and product development. Overall, Gamida Cell has an excellent reputation in the biotech industry. The company has shown that it can play a leading role in the development of cell therapies that can improve the lives of patients with severe diseases. With the growing demand for new treatment options and the rapid progress in the field of biotech, Gamida Cell is well positioned to continue expanding and developing new therapies that have the potential to change the lives of millions of people worldwide. Gamida Cell ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Gamida Cell's EBIT
Gamida Cell's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Gamida Cell's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Gamida Cell's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Gamida Cell’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Gamida Cell stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Gamida Cell.
How has the EBIT of Gamida Cell developed in recent years?
The EBIT of Gamida Cell has increased by -0.471% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Gamida Cell?
The EBIT of Gamida Cell is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Gamida Cell pay?
Over the past 12 months, Gamida Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gamida Cell is expected to pay a dividend of 0 USD.
What is the dividend yield of Gamida Cell?
The current dividend yield of Gamida Cell is .
When does Gamida Cell pay dividends?
Gamida Cell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Gamida Cell?
Gamida Cell paid dividends every year for the past 0 years.
What is the dividend of Gamida Cell?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Gamida Cell located?
Gamida Cell is assigned to the 'Health' sector.
Wann musste ich die Aktien von Gamida Cell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Gamida Cell from 12/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.
When did Gamida Cell pay the last dividend?
The last dividend was paid out on 12/4/2024.
What was the dividend of Gamida Cell in the year 2023?
In the year 2023, Gamida Cell distributed 0 USD as dividends.
In which currency does Gamida Cell pay out the dividend?
The dividends of Gamida Cell are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Gamida Cell
Our stock analysis for Gamida Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gamida Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.